RECIPHARM AB [CBOE] overview

Recipharm Harmonizes its Global Quality Operations with Veeva Vault Quality PR Newswire PLEASANTON, Calif., Dec. 19, 2023 Leading CDMO adopts Veeva Vault QMS, Vault QualityDocs, and Vault Training to standardize quality processes and manage GxP content across its organization PLEASANTON, Calif. , Dec. 19, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Recipharm , a global contract development and manufacturing organization (CDMO), will use Veeva Vault QMS , Veeva Vault...

HONEYWELL AND RECIPHARM TO SPEED DEVELOPMENT OF INHALERS WITH A NEAR-ZERO GLOBAL WARMING POTENTIAL PROPELLANT PR Newswire MORRIS PLAINS, N.J. and STOCKHOLM, Aug. 17, 2023 Partnership will reduce environmental footprint of pressurized metered dose inhalers and accelerate transition to lower greenhouse gas respiratory care. MORRIS PLAINS, N.J. and STOCKHOLM , Aug. 17, 2023 /PRNewswire/ -- Honeywell (Nasdaq: HON) and global contract development and manufacturing organization (CDMO) Recipharm have...

Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with leading Contract Development and Manufacturing Organisation (CDMO), Recipharm . Under the agreement, Stevanato Group will lend its 70+ years of manufacturing experience to support the development and production of pre-fillable syringes for use in Recipharm’s soft mist...

Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”) announced today that it has acquired Aesica Pharmaceuticals Limited (“The Cramlington Site”) from Recipharm group. The Cramlington Site in Newcastle, United Kingdom, has an established history of cGMP manufacturing services for an array of Active Pharmaceutical Ingredients (API), ranging from pilot scale to commercial metric ton scale. The Cramlington Site has more than 100 cubic meter reactor commercial...

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a leading contract development and manufacturing organization (CDMO), today confirmed that following the European Medicines Agency’s (EMA) Committee for Human Medicines (CHMP) approval of the Recipharm Monts site on June 11, 2021, drug product manufacture of the Moderna COVID-19 vaccine at the site in France has now begun. “We are proud to be working...

Moderna, Inc. (NASDAQ:MRNA), biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a leading contract development and manufacturing organization (CDMO), today announced that they have reached an agreement to support formulation and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The activity will be performed in Recipharm’s drug product manufacturing facility located in France. Subject to regulatory approval...

Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB: ASPF) today announced that it has commenced litigation against Recipharm Limited (“Recipharm”), a wholly-owned subsidiary of Recipharm AB (RECI-B.ST), in the Commercial Court of London. Acerus alleges that the suspension of Recipharm’s manufacturing license in August 2018, in contravention of its contractual obligations to Acerus, led to a shortage of Estrace ® in Canada. In 2018, Estrace ® generated...